Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced or Recurrent Solid Tumors|Breast Neoplasms|Ovarian Cancer, Epithelial|Ewing Sarcoma|Small Cell Lung Carcinoma|Prostate Cancer|Pancreas Cancer
Interventions: DRUG: Talazoparib
Sponsor: Pfizer
Collaborators: Medivation, Inc.